Curated News
By: NewsRamp Editorial Staff
April 08, 2026
Aclarion Partners with Weill Cornell to Advance Chronic Back Pain Diagnosis
TLDR
- Aclarion's commercial agreement with Weill Cornell Medicine expands Nociscan's clinical validation, potentially giving the company a competitive edge in the chronic pain diagnostics market.
- Nociscan uses MRI spectroscopy data, proprietary algorithms, and chemical biomarkers to noninvasively identify painful discs in the spine, helping physicians optimize treatment strategies.
- This technology could improve treatment for millions suffering from chronic back pain worldwide by providing more accurate diagnosis and personalized care approaches.
- Aclarion's Nociscan is the first evidence-supported SaaS platform that objectively quantifies chemical biomarkers associated with disc pain using augmented intelligence algorithms.
Impact - Why it Matters
This development matters because chronic low back pain represents one of the most widespread and debilitating health conditions globally, affecting hundreds of millions of people and costing healthcare systems billions annually. Traditional diagnostic approaches often struggle to pinpoint the exact source of disc-related pain, leading to ineffective treatments, prolonged suffering, and unnecessary procedures. Nociscan's biomarker-based approach offers a more precise, noninvasive method for identifying painful discs, potentially revolutionizing how physicians diagnose and treat this pervasive condition. The collaboration with Weill Cornell Medicine, a leading academic medical center, validates the technology's potential and accelerates its integration into mainstream spine care. For patients, this could mean more accurate diagnoses, targeted treatments, reduced trial-and-error approaches, and ultimately better pain management outcomes. The technology's ability to objectively quantify pain biomarkers represents a significant advancement beyond subjective pain reporting, potentially transforming clinical decision-making for one of healthcare's most challenging conditions.
Summary
In a significant advancement for chronic low back pain treatment, Aclarion, Inc. has established a commercial agreement with Weill Cornell Medicine to expand the use of its innovative Nociscan technology. This collaboration brings Aclarion's evidence-supported SaaS platform to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center, where it will be integrated into a groundbreaking clinical trial led by triple-board certified physician Dr. Jaspal Ricky Singh. The trial, entitled "A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease," aims to investigate how the dose and quantity of bone marrow aspirate stem cell concentrate affects patient outcomes, with Nociscan providing critical diagnostic insights for a subset of spine patients selected through Dr. Singh's clinical evaluation.
Nociscan represents a revolutionary approach to diagnosing chronic low back pain, which affects approximately 266 million people worldwide suffering from degenerative spine disease. As the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine, Nociscan objectively quantifies chemical biomarkers associated with disc pain using Magnetic Resonance Spectroscopy data from MRI machines. The technology employs proprietary signal processing techniques and augmented intelligence algorithms to provide physicians with critical insights into the precise location of a patient's low back pain, ultimately improving treatment strategies and patient outcomes when all Nociscan-positive discs are addressed.
Dr. Singh emphasized the importance of this technology in his comprehensive approach to spinal disorder treatment, stating that their pioneering research into discogenic low back pain and concentrated bone marrow aspirate creates an ideal opportunity to utilize Nociscan's insights. For those seeking more information about this innovative technology, additional details can be found through the company's Latest News portal, and patients can locate Nociscan centers using the provided site map. This partnership between Aclarion and Weill Cornell Medicine represents a meaningful step forward in addressing one of healthcare's most pervasive challenges through cutting-edge technology and collaborative research.
Source Statement
This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, Aclarion Partners with Weill Cornell to Advance Chronic Back Pain Diagnosis
